A single 120-bed Uganda hospital serving the military — dressed as a pan-African platform

• UMC Victoria, Kampala (~75% of revenue). 120 beds, 72% occupancy, ARPOB jumped from ₹24K to ₹40K via IVF, spine, ICU add-ons. Uganda MoD is the anchor payer.
• India expansion (the thesis). Asset-light leased hospitals in Maharashtra — Navi Mumbai (52 beds, live Oct 2025), Nashik (200 beds, Jan–Feb 2026), Pune (125 beds, FY27).
• Tail verticals. Distribution, consultancy, medical value travel contribute ~18% of revenue. Exited Nigeria; Mwanza (Tanzania) secondary care added.

Record profits, negative cash flow — the P&L is a promissory note

Revenue compounded 21% to ₹56 Cr in FY25; H1 FY26 hit ₹67 Cr. But 3-year cumulative CFO is ₹3 Cr on ₹33 Cr PAT — 9% cash conversion vs 70–90% for listed peers.

B- governance — frugal founders, undersized board for a five-country empire

• Ownership. Promoters hold 69.14% (edging up), zero pledge, zero FII. Founders extended personal loans to the company — rare skin-in-the-game for an SME.
• Pay. MD Dr. Akshay Parmar draws ₹60 lakhs (1.2% of revenue). Co-founder Dr. Anurag Shah draws zero. Total director pay ₹72 lakhs — genuinely frugal.
• Board gap. 5-member board, only 2 independents (both post-IPO, under 3 yrs tenure), audit committee meets 3×/year. No Africa-ops or hospital-chain expertise.
• Related-party web. ₹80 Cr annual RPT limit approved across India/Mauritius/Tanzania/Uganda subsidiaries — material against ₹58 Cr consolidated revenue.

From Mumbai medical-tour startup to Africa operator — now betting the shop on India

2010–2023: The Africa Build. Two MBBS classmates incorporated Unihealth in 2010, built hospitals in Uganda and Nigeria, and listed on NSE Emerge in Sep 2023 at ₹132 promising 1,000 beds by FY26. Thirteen years of quiet bootstrapping ended with a tepid listing and an ambitious deck.

2024–2026: The Pivot Back Home. The 1,000-bed target quietly became a 'medium-term vision' (actual: 252 beds). Nigeria exited after the Naira crash. A 10-year Uganda tax holiday kicked in Jul 2024, margins exploded to 48%, and the stock rose 3.4× from IPO. Navi Mumbai live Oct 2025; Nashik slipping to Jan–Feb 2026.

Micro-cap rerated 3.4× on an expansion narrative that has barely begun to execute

• Morningstar overvaluation flag. Quant model assigns a 127% premium to fair value despite a headline P/E half the sector (16× vs 28–55×) — the model says the growth is already priced in.
• 85% surge in 7 sessions. TradeBrains flagged a speculative burst on expansion buzz in a stock with ~30% public float, 1,058 shareholders, and zero FII — momentum, not research-driven.
• FY26 results imminent. Trading window closed Apr 1, 2026 ahead of audited FY26 numbers — first full period capturing Navi Mumbai, Nashik, and the Uganda tax-holiday tailwind.

Three concentrations that could each reprice the stock 30–40%

• Sovereign receivable. ₹82 Cr of ₹112 Cr receivables sit with the Ugandan Ministry of Defense on a 9–13 month cycle. An impairment or restructuring would wipe ~1.5× FY25 PAT off the balance sheet.
• India execution. Nashik 200-bed must hit 30%+ occupancy within 12 months against Apollo, Fortis, and Sahyadri — with a 500-person team and two founders split across continents.
• Margin mirage. 48% H1 FY26 OPM flatters a mature Uganda hospital on a 4% tax rate. Indian facilities ramp at 15–18% EBITDA on normal tax — blended margins will compress sharply in FY27.